



Computer Science, Engineering and Technology

Vol: 3(4), December 2025

REST Publisher; ISSN: 2583-9179

Website: <https://restpublisher.com/journals/cset/>

DOI: <https://doi.org/10.46632/cset/3/4/7>



Computational Modeling of Personalized Cancer Treatments: Integrating Genomics, Immunotherapy, and Targeted Treatments using DEMATEL Method

*Chandrasekar Raja, Ramya Sharma, M. Ramachandran, Muniyammal Sakthivel

REST Labs, Kaveripattinam, Krishnagiri, Tamil Nadu, India.

*Corresponding Author Email: chandrasekarsri@gmail.com

Abstract: The advent of precision medicine has marked a new Head and neck in cancer treatment, where therapeutic approaches are customized of each patient tumor individual genetics and molecular based on the characteristics. Standard practice now involves genomic profiling, which allows clinicians to pinpoint specific genetic mutations and alterations responsible for driving cancer growth. Armed with this information, targeted therapies can be chosen to disrupt these particular pathways. Additionally, liquid biopsies provide a non-invasive method for monitoring genetic changes over time, assisting in treatment adjustments and the identification of resistance mechanisms. The research significance lies not only in these individual advancements but in their synergistic integration. Comprehensively understanding the genomic landscape allows for the identification of actionable targets, which can then be exploited by targeted therapies. The interplay between genomics and immunotherapy, as well as the potential additive or synergistic effects of combined treatments, are areas of active investigation. Furthermore, the incorporation of personalized therapies into clinical practice represents a shift towards more individualized and effective treatment strategies. This is particularly crucial in head and neck cancer, where heterogeneity in tumor biology necessitates tailored approaches for optimal outcomes. As these advancements progress, ongoing clinical trials play a pivotal role in validating their efficacy, safety, and long-term impact on patient survival and quality of life. Personalized Medicine and Genomic Profiling, Public Health Initiatives and Prevention, Epidemiology and Risk Factors, Clinical Presentation and Diagnosis and Treatment Modalities. the DEMATEL-based ranking of Advancements in Personalized Therapies for Head and Neck Cancer, Personalized Medicine and Genomic Profiling secure the top position, while Clinical Presentation and Diagnosis obtain the lowest rank.

Keywords: Personalized Medicine and Genomic Profiling, Public Health Initiatives and Prevention, Epidemiology and Risk Factors, Clinical Presentation and Diagnosis and Treatment Modalities.

1. INTRODUCTION

Advancements in personalized therapies represent a paradigm shift in the field of medicine, tailoring treatment approaches Precision medicine allows customization of treatments for individual patients by considering their distinct genetic, molecular, and clinical characteristics. more targeted and effective approach to managing various diseases, including cancer. Genomic profiling and molecular diagnostics play pivotal roles in identifying specific genetic alterations or biomarkers associated with a patient's condition. This information allows healthcare professionals to select therapies that have a higher likelihood of success minimize potential side effects. The integration of technologies such as next-generation sequencing has significantly enhanced our understanding of the genetic basis of diseases, paving the way for the development of novel, highly targeted therapeutics [1]. As personalized therapies continue to evolve, the focus shifts towards combining genomic data with other omics information, real-time monitoring, and advanced data analytics, fostering a comprehensive and dynamic approach to patient care. The ongoing progress in personalized therapies holds the promise of improving treatment outcomes, reducing adverse effects, and ultimately transforming the landscape of healthcare into a more individualized and precise endeavor. Head and neck cancer is the head and neck in anatomical systems of developing cancers denotes the set, It includes the oral cavity, larynx,

Paranasal sinuses, Nasal cavity and saliva Includes gland [2]. This diverse category of cancers encompasses various histological types, with the most prevalent type being cancer of the squamous cells. Human papillomavirus (HPV) infection, consumption of alcohol and cigarettes, and exposure to some occupational carcinogens are causes for head and neck cancers. a number of variables, such as cancer's exact location, distinct cancers of the head and neck and indications may origin, but common signs include persistent sore throat, difficulty swallowing, changes in voice, and lumps or sores that do not heal. Early detection is crucial for successful treatment, which may entail treatment such as chemotherapy, therapy with radiation, and surgery together. In an effort to enhance patient outcomes and survival rates, multidisciplinary strategies, such as therapy and healing, are frequently used to address the numerous issues connected with cancer of the skull and neck [3]. Regular screenings, lifestyle modifications, and vaccination against HPV are essential preventive measures in managing the incidence of carcinoma of the head and neck. Squamous cell tumors of the head and neck (HNSCC) is a leading cause significant morbidity and death worldwide, mainly associated with substance use. The delayed initiation of medical treatment and the advanced disease presentation contribute to over 300,000 annual deaths. Although a comprehensive, multidisciplinary approach is often necessary for Despite treatment efforts, the United States has a 5-year survival rate of only 40%, primarily attributable to the scarcity of effective choices for cancers in advanced stages [4]. Relapse is frequently observed in cases of geographically advanced disease, even with early intervention; traditional treatments generate only 30–40% responses, and an average survival time is 6–9 months. This leads to a poor prognosis. Conventional chemotherapy, renowned for its unfavorable effects and poor tumor selectivity, faces challenges due to a myriad of gene mutations in HNSCC, some of which contribute to treatment failure. Notably, the EGFR variant and mutations in the PI3KCA gene play significant roles. While EGFR vIII imparts resistance to EGFR inhibitors, and about one-third of HNSCC tumors PIK3CA (E542K) mutation PI3K pathway with to the inhibitor BEZ-325 shows sensitivity [5]. The heterogeneity in mutations poses difficulties in developing small molecules or antibodies targeting each oncogenic mutation. Consequently, nucleic acid therapy emerges as a viable option to reduce the Personalized possibilities a higher order of deliverables mutant with specification expression of genes oncology treatment. In this context, advancements in gene delivery systems play a crucial role. While direct intravenous administration of therapeutic nucleic acids allows for evidence-based surveys, accessibility limitations and low translocation efficiency hinder its efficacy in deep-seated tumors. To overcome these challenges, vector development has progressed, including liposomes, nanoparticles, and virus vectors. These advancements enhance the distribution, transfer efficiency, and protection of nucleic acids, but concerns related to hematologic toxicity, hepatotoxicity, and innate immune responses persist [6]. The next generation of liposomes aims to address these concerns and improve tumor specificity, underscoring the ongoing efforts to harness Utilizing gene delivery systems for Head and Neck Squamous Cell Carcinoma (HNSCC) presents a targeted therapy approach focused on nucleic acids. Integrating genomics into healthcare represents a transformative approach that holds immense promise for personalized medicine and improved patient outcomes. Genomics, the study of an individual's entire set of genes, provides insights into the genetic variations that contribute to health and disease. By incorporating genomic information into clinical practice, healthcare professionals can tailor medical interventions to an individual's unique genetic profile, enabling more precise diagnoses, targeted therapies, and personalized treatment plans [7]. Advances in genomic technologies, such as next-generation sequencing, have accelerated our ability to analyze large sets of genetic data quickly and cost-effectively. This wealth of information allows clinicians to identify genetic predispositions, assess disease risk, and determine optimal drug responses. As genomics continues to evolve, its integration into routine clinical care has the potential to revolutionize disease prevention, early detection, and therapeutic decision-making. However, challenges such as ethical considerations, data privacy, and the need for education among healthcare providers and the public Genes are responsible and in an equal manner Ensure implementation have to do medicine on a broader scale [8]. Efforts to integrate genomics into healthcare require collaborative initiatives among researchers, clinicians, policymakers, and the broader community to harness the full potential of genomic information for the benefit of individual patients and public health. Immunotherapy marks a new change in cancer care that targets cancer cells by boosting the immune system's function of the body. Unlike traditional methods such as radiation and chemotherapy, which attack cancerous cells directly, therapy works by enhancing the capacities of the immune system to identify and fight cancer cells [9]. Key approaches Include immunological checkpoint blockers, therapeutic vaccinations, and adoptive cell transplantation in the management of cancer. Immune checkpoint antagonists work by obstructing inhibitory signals. Two examples of such inhibitors are cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors and designed cell death protein 1 (PD-1). By doing this, the body's defense system is freed up to mount a stronger defense versus cancer. Developing the individual's own immune cells—such as T cells—outside of the body followed by returning them to fight cancer is known as therapeutic cell transfer cells. Therapeutic vaccines are designed to stimulate the immune system specifically to recognize and combat cancer antigens. The field of immunotherapy has witnessed notable success across various cancers, resulting in enduring responses and extended survival in select patients. While not universally effective, ongoing research aims to

refine and expand the application of immunotherapy, uncover biomarkers for patient selection, and mitigate potential side effects [10]. As a rapidly evolving field, immunotherapy continues to offer new hope for patients by revolutionizing the landscape of cancer treatment. Targeted treatments, also known as precision or personalized medicine, represent a revolutionary approach to medical intervention. These therapies focus on specific molecular or genetic characteristics of an individual's disease, allowing for more precise and effective treatment strategies. Unlike traditional treatments that may have a broader impact on the body, targeted treatments are designed to selectively target the underlying causes of a particular condition, minimizing side effects and maximizing therapeutic benefits [11]. This personalized approach is particularly prominent in the field of oncology, where therapies are tailored to the genetic makeup of a patient's tumor, leading to improved outcomes and reduced harm to healthy tissues. Precision medicine, commonly referred to as targeted treatments, marks a groundbreaking advancement in healthcare. This innovative approach zeroes in on the unique molecular or genetic aspects of a person's illness, enabling more accurate and efficient therapeutic interventions [12]. In contrast to conventional treatments with broader systemic effects, targeted therapies specifically address the root causes of a specific ailment, mitigating adverse reactions and optimizing treatment efficacy. This individualized methodology is notably evident in oncology, where treatments are customized of the patient's tumor based on genetic makeup, resulting in enhanced results and diminished impact on healthy bodily tissues [13].

2. MATERIALS AND METHOD

Personalized Medicine and Genomic Profiling: Personalized medicine, a groundbreaking approach in healthcare, emphasizes Customizing treatments for individual patients according to their distinctive genetic composition. Genomic profiling, a key component of personalized medicine, involves analyzing the genetic information of patients to identify specific mutations or variations that may drive diseases such as concerning carcinoma of the head as well as neck. Regarding cancer from the head had along with neck, genomic profiling enables a deeper understanding of the molecular characteristics of tumors, guiding clinicians in selecting targeted therapies that are more precise and potentially more effective. Challenges in this field include the need for comprehensive genomic databases, ethical considerations surrounding genetic information, and the integration of genomic data into routine clinical practice.

Public Health Initiatives and Prevention: Public health initiatives play a vital role in preventing head and neck cancers by addressing modifiable risk factors and promoting awareness. These initiatives encompass a range of strategies, including educational campaigns on the dangers of Tobacco and alcohol application, healthy Lifestyle choices Upgrading and Human papillomavirus (HPV). for high-risk strains vaccination programs against Successful prevention relies on community involvement, requiring collaborative efforts to overcome challenges such as socio-economic disparities, cultural beliefs, and limited access to healthcare services. By focusing on prevention, public health initiatives aim to reduce Head and neck Incidence of cancers and them improve overall community health.

Epidemiology and Risk Factors: Understanding the skull and cervical carcinoma epidemic and warning signs is essential for effective disease management as well as defense. Variability in throat and head malignancies is seen in prevalence across different regions and populations. Common risk factors encompass tobacco and alcohol use, HPV infection, occupational exposures to carcinogens, and dietary habits. This knowledge informs public health strategies aimed at reducing exposure to these risk factors and emphasizes the importance of early detection through regular screenings. By addressing both modifiable and non-modifiable risk factors, healthcare professionals can work towards reducing Head and neck burden of cancers on a global scale.

Clinical Presentation and Diagnosis: The clinical presentation and timely Methods for diagnosing head and neck cancer include paramount for successful treatment outcomes. Patients often present with symptoms such as persistent sore throat, difficulty swallowing, and changes in voice. Diagnosing Head and neck to manage cancer a versatility is required approach, integrating clinical examination, imaging techniques (CT, MRI, PET scans), and biopsy. The complex. The anatomy of the head and neck region requires the collaboration of specialists, including surgeons, oncologists, radiologists, and pathologists, to accurately diagnose the type, stage, and extent of the cancer. Early and precise diagnosis facilitates the development of tailored treatment plans, improving Chances of success interventions.

Treatment Modalities: Head and neck cancer treatment modalities encompass a multidimensional approach tailored to the specific characteristics of each case. Surgical intervention is often a primary treatment, with the extent depending on the tumor's location and stage. Radiation therapy, either leveraging either standalone or combined approaches with

surgery or chemotherapy, the objective is to specifically target cancer cells while minimizing harm to adjacent healthy tissue. Chemotherapy, delivered systemically, may be utilized in conjunction with other modalities. Notably, immunotherapy is emerging as a promising Avenue, cancer cells Identify and remove the immune system of the body using Zone is a key focus. With ongoing research, there is a growing emphasis on integrating these diverse treatment modalities continues to evolve, offering new hope for improved outcomes and enhancing the standard of living for those suffering from neck and head cancers.

Method: The DEMATEL method serves as a specialized approach for addressing specific problems characterized by interconnected issues. It involves identifying interdependencies among problems, establishing a hierarchical structure, and modeling potential solutions to create a workable system. The DEMATEL method contributes to a comprehensive understanding by utilizing directional charts and view charts. It finds application in various domains, including emergency management systems, where it integrates seamlessly with existing management practices. In this proposed method, the DEMATEL approach is employed to decompose fuzzy numbers, a step that was not explicitly required in prior methods [14]. The core principle of DEMATEL is fundamentally organized, constituting a method for visualizing and analyzing complex issues systematically. This method employs structured modeling to address problems and generate solutions. The structured approach involves creating graphical representations that depict the interrelated relationships and factors among various elements. The visualization takes the form of a graph, illustrating the cause-and-effect relationships between systemic factors. Through analysis, these elements are categorized into causal groups, distinguishing between causes, groups, and outcomes. Particularly in the context of computer Components [15]. The DEMATEL method provides researchers with frameworks to better understand relationships, aiding in the resolution of intricate computer-related issues. When applied to benchmarking, this method effectively calculates relationships between effects, making it suitable for assessing complex systems with multiple components, such as sender-receiver systems. Furthermore, it offers a valuable tool for managing resources and planning implementations, allowing organizations to make optimal choices and address challenges effectively [16]. Decision-makers face the challenge of identifying potent constraints within the legal framework that exert a significant impact and may impede or influence their objectives. The confirmation of such constraints is crucial for devising strategies to minimize their effects. Both the ISM (Interpretive Structural Modeling) and DEMATEL methods provide results that are somewhat aligned in this context. When applied to the management of e-waste, the combination of ISM and DEMATEL results not only establishes a structural framework but also reveals the interactions among these obstacles. In essence, the combined findings not only highlight the structural aspects of the identified constraints but also shed light on the intricate web of relationships between them [17]. Consequently, an initial deficiency was identified in the DEMATEL approach, specifically within the first cluster. When comparing test makers' opinions on various topics, including the assignment of weights, it was discovered that they are now operating collaboratively as a team. Interestingly, mindfulness serves as a connection in decision-making, highlighting a shift in the team's approach. Evidently, in a group decision-making dilemma, regular decision-makers consistently rely on their own judgment and the input of other test makers, believing that the widespread acceptance of their assessments is imminent [18]. The cumulative interplay among factors and the examination of their relationships, specifically their cause-and-effect dynamics, is commonly addressed using the DEMATEL approach for categorization. This method is widely acknowledged and embraced for its effectiveness. Consequently, each source considered in this article is regarded as a benchmark when deciding the source's influence. Employing DEMATEL, the significance and level of importance of each source can be effectively determined, yielding optimal results [19]. The propositions associated with bodies of evidence undergo transformation, and an Integrated Multi-Dimensional Decision Making (MCDM) approach is employed to assess the causation among criteria for evaluating an outreach worker program. In addition to fostering relationships, the DEMATEL technique is incorporated. This integration of DEMATEL and a newly introduced cluster-weighted system, encompassing a discussion system, serves as a comprehensive framework for a company. It aids in visualizing the intricate structure of relationships between criteria and is instrumental in measuring the influence of these criteria [20]. The current study is framed by the initial application of the DEMATEL technique and its foundational definition, marking the inception of this method. The original formulation of the DEMATEL method lacked a specific structure and was introduced without a clear framework. Advances in the DEMATEL technique have been proposed to address its undisclosed shortcomings and enhance its efficiency [21].

3. RESULT AND DISCUSSION

TABLE 1. Advancements in Personalized Therapies for Head and Neck Cancer

	Software Transactional Memory (STM)	Read-Write Locks	Atomic Operations	Thread-Safe Data Structures	Immutable Data	Sum
Personalized Medicine and Genomic Profiling	0	2	4	2	3	11
Public Health Initiatives and Prevention	3	0	2	1	2	8
Epidemiology and Risk Factors	2	4	0	1	2	9
Clinical Presentation and Diagnosis	1	1	2	0	2	6
Treatment Modalities	2	2	1	2	0	7

Table 1 shows that DEMATEL Decision making trail and evaluation laboratory in Advancements in Personalized Therapies for Head and Neck Cancer with respect to Personalized Medicine and Genomic Profiling, Public Health Initiatives and Prevention, Epidemiology and Risk Factors, Clinical Presentation and Diagnosis and Treatment Modalities it is also sum of Value.




FIGURE 1. Advancements in Personalized Therapies for Head and Neck Cancer

Figure 1 shows that DEMATEL Decision making trail and evaluation laboratory in Advancements in Personalized Therapies for Head and Neck Cancer with respect to Personalized Medicine and Genomic Profiling, Public Health Initiatives and Prevention, Epidemiology and Risk Factors, Clinical Presentation and Diagnosis and Treatment Modalities it is also sum of Value.

TABLE 2. Normalization of Direct Relation Matrix

Normalization of direct relation matrix					
	Software Transactional Memory (STM)	Read-Write Locks	Atomic Operations	Thread-Safe Data Structures	Immutable Data
Personalized Medicine and Genomic Profiling	0	0.181818182	0.36363636	0.181818182	0.272727273
Public Health Initiatives and Prevention	0.272727273	0	0.18181818	0.090909091	0.181818182
Epidemiology and Risk Factors	0.181818182	0.363636364	0	0.090909091	0.181818182
Clinical Presentation and Diagnosis	0.090909091	0.090909091	0.18181818	0	0.181818182
Treatment Modalities	0.181818182	0.181818182	0.09090909	0.181818182	0

Table 2 shows that the Normalizing of direct relation matrix in Advancements in Personalized Therapies for Head and Neck Cancer with respect to Personalized Medicine and Genomic Profiling, Public Health Initiatives and Prevention, Epidemiology and Risk Factors, Clinical Presentation and Diagnosis and Treatment Modalities the diagonal value of all the data set is zero.


**FIGURE 2.** Normalization of Direct Relation Matrix

Figure 2 shows that the Normalizing of direct relation matrix in Advancements in Personalized Therapies for Head and Neck Cancer with respect to Personalized Medicine and Genomic Profiling, Public Health Initiatives and Prevention, Epidemiology and Risk Factors, Clinical Presentation and Diagnosis and Treatment Modalities of all the data set is zero.

TABLE 3. Calculate the Total Relation Matrix

Calculate the total relation matrix					
	Software Transactional Memory (STM)	Read-Write Locks	Atomic Operations	Thread-Safe Data Structures	Immutable Data
Personalized Medicine and Genomic Profiling	0	0.181818182	0.363636364	0.181818182	0.27272727
Public Health Initiatives and Prevention	0.272727273	0	0.181818182	0.090909091	0.18181818
Epidemiology and Risk Factors	0.181818182	0.363636364	0	0.090909091	0.18181818
Clinical Presentation and Diagnosis	0.090909091	0.090909091	0.181818182	0	0.18181818
Treatment Modalities	0.181818182	0.181818182	0.090909091	0.181818182	0

Table 3 Shows the Calculate the total relation matrix in shows that DEMATEL Decision making trail and evaluation laboratory in Advancements in Personalized Therapies for Head and Neck Cancer with respect to Personalized Medicine and Genomic Profiling, Public Health Initiatives and Prevention, Epidemiology and Risk Factors, Clinical Presentation and Diagnosis and Treatment Modalities is Calculate the Value.

TABLE 4. $T = Y(I - Y)^{-1}$ I= Identity matrix

I				
1	0	0	0	0
0	1	0	0	0
0	0	1	0	0
0	0	0	1	0
0	0	0	0	1

Table 4 Shows the $T = Y(I - Y)^{-1}$, I= Identity matrix in Advancements in Personalized Therapies for Head and Neck Cancer with respect to Personalized Medicine and Genomic Profiling, Public Health Initiatives and Prevention, Epidemiology and Risk Factors, Clinical Presentation and Diagnosis and Treatment Modalities is the common Value.

TABLE 5. Y Value

Y				
0	0.181818	0.363636	0.181818	0.272727
0.272727	0	0.181818	0.090909	0.181818
0.181818	0.363636	0	0.090909	0.181818
0.090909	0.090909	0.181818	0	0.181818
0.181818	0.181818	0.090909	0.181818	0

Table 5 Shows the Y Value in Advancements in Personalized Therapies for Head and Neck Cancer with respect to Personalized Medicine and Genomic Profiling, Public Health Initiatives and Prevention, Epidemiology and Risk Factors, Clinical Presentation and Diagnosis and Treatment Modalities is the Calculate the total relation matrix Value and Y Value is the same value.

TABLE 6. I-Y Value

I-Y				
1	-0.18182	-0.36364	-0.18182	-0.27273
-0.27273	1	-0.18182	-0.09091	-0.18182
-0.18182	-0.36364	1	-0.09091	-0.18182
-0.09091	-0.09091	-0.18182	1	-0.18182
-0.18182	-0.18182	-0.09091	-0.18182	1

Table 6 Shows the I-Y Value Advancements in Personalized Therapies for Head and Neck Cancer with respect to Personalized Medicine and Genomic Profiling, Public Health Initiatives and Prevention, Epidemiology and Risk Factors, Clinical Presentation and Diagnosis and Treatment Modalities table 4 $T = Y(I-Y)^{-1}$, I= Identity matrix and table 5 Y Value Subtraction Value.

TABLE 7. (I-Y)-1 Value

(I-Y)-1				
1.616736402	0.848954	0.933891	0.615481	0.876987
0.710460251	1.543096	0.683682	0.455509	0.68145
0.69539749	0.869038	1.56318	0.478243	0.718828
0.441004184	0.484937	0.528033	1.269596	0.535286
0.566527197	0.602092	0.532218	0.469038	1.446025

Table 7 shows the (I-Y)-1 Value in Advancements in Personalized Therapies for Head and Neck Cancer with respect to Personalized Medicine and Genomic Profiling, Public Health Initiatives and Prevention, Epidemiology and Risk Factors, Clinical Presentation and Diagnosis and Treatment Modalities Table 6 show the Minverse Value.

TABLE 8. Total Relation matrix (T)

	Total Relation matrix (T)					Ri
Personalized Medicine and Genomic Profiling	0.616736402	0.848954	0.933891	0.615481	0.876987	3.89205
Public Health Initiatives and Prevention	0.710460251	0.543096	0.683682	0.455509	0.68145	3.074198
Epidemiology and Risk Factors	0.69539749	0.869038	0.56318	0.478243	0.718828	3.324686
Clinical Presentation and Diagnosis	0.441004184	0.484937	0.528033	0.269596	0.535286	2.258856
Treatment Modalities	0.566527197	0.602092	0.532218	0.469038	0.446025	2.6159
Ci	3.030125523	3.348117	3.241004	2.287866	3.258577	

Table 8 shows the Total Relation Matrix the direct relation matrix is multiplied with the inverse of the value that the direct relation matrix is subtracted from the identity matrix.




FIGURE 3. Total Relation Matrix

Figure 3 shows the Total Relation Matrix the direct relation matrix is multiplied with the inverse of the value that the direct relation matrix is subtracted from the identity matrix.

TABLE 9. Techniques for Managing Concurrent Access to Shared Data Ri, Ci Value

	Ri	Ci
Personalized Medicine and Genomic Profiling	3.89205	3.030126
Public Health Initiatives and Prevention	3.074198	3.348117
Epidemiology and Risk Factors	3.324686	3.241004
Clinical Presentation and Diagnosis	2.258856	2.287866
Treatment Modalities	2.6159	3.258577

Table 9 shows the Advancements in Personalized Therapies for Head and Neck Cancer, Personalized Medicine and Genomic Profiling, Public Health Initiatives and Prevention, Epidemiology and Risk Factors, Clinical Presentation and Diagnosis and Treatment Modalities Ri Value Personalized Medicine and Genomic Profiling is showing the Highest Value for Ri and Clinical Presentation and Diagnosis is showing the lowest value. Public Health Initiatives and Prevention is showing the Highest Value for Ci and Clinical Presentation and Diagnosis is showing the lowest value.


**FIGURE 4.** Total Relation Matrix (T) Ri, Ci Value

Figure 4 shows the Advancements in Personalized Therapies for Head and Neck Cancer, Personalized Medicine and Genomic Profiling, Public Health Initiatives and Prevention, Epidemiology and Risk Factors, Clinical Presentation and Diagnosis and Treatment Modalities Ri Value Personalized Medicine and Genomic Profiling is showing the Highest Value for Ri and Clinical Presentation and Diagnosis is showing the lowest value. Public Health Initiatives and Prevention is showing the Highest Value for Ci and Clinical Presentation and Diagnosis is showing the lowest value.

TABLE 10. Calculation of Ri+Ci and Ri-Ci to Get the Cause and Effect

	Ri+Ci	Ri-Ci	Rank	Identity
Personalized Medicine and Genomic Profiling	6.922176	0.861925	1	cause
Public Health Initiatives and Prevention	6.422315	-0.27392	3	effect
Epidemiology and Risk Factors	6.56569	0.083682	2	cause
Clinical Presentation and Diagnosis	4.546722	-0.02901	5	effect
Treatment Modalities	5.874477	-0.64268	4	effect

Table 10 shows the Calculation of Ri+Ci and Ri-Ci to Get the Cause and Effect. Advancements in Personalized Therapies for Head and Neck Cancer are Personalized Medicine and Genomic Profiling, Public Health Initiatives and

Prevention, Epidemiology and Risk Factors, Clinical Presentation and Diagnosis and Treatment Modalities. of Personalized Medicine and Genomic Profiling, Epidemiology and Risk Factors is showing the highest Value of cause. Public Health Initiatives and Prevention, Clinical Presentation and Diagnosis and Treatment Modalities is Showing the lowest Value of effect.

TABLE 11. T Matrix Value

T Matrix					
Personalized Medicine and Genomic Profiling	0.616736	0.848954	0.933891	0.615481	0.876987
Public Health Initiatives and Prevention	0.71046	0.543096	0.683682	0.455509	0.68145
Epidemiology and Risk Factors	0.695397	0.869038	0.56318	0.478243	0.718828
Clinical Presentation and Diagnosis	0.441004	0.484937	0.528033	0.269596	0.535286
Treatment Modalities	0.566527	0.602092	0.532218	0.469038	0.446025

Table 11 Compute the mean of the values in the T Matrix and identify the threshold value (Alpha) as 0.606627615. Bold any T matrix element surpassing the specified threshold.




FIGURE 5. Shown the Rank

Figure 5 shows in the DEMATEL-based ranking of Advancements in Personalized Therapies for Head and Neck Cancer, Personalized Medicine and Genomic Profiling secure the top position, while Clinical Presentation and Diagnosis obtain the lowest rank.

4. CONCLUSION

The advent of precision medicine has marked a new Head and neck in cancer treatment, where therapeutic approaches are customized of each patient tumor individual genetics and molecular based on the characteristics. Standard practice now involves genomic profiling, which allows clinicians to pinpoint specific genetic mutations and alterations responsible for driving cancer growth. Armed with this information, targeted therapies can be chosen to disrupt these particular pathways. Additionally, liquid biopsies provide a non-invasive method for monitoring genetic changes over time, assisting in treatment adjustments and the identification of resistance mechanisms. Notably, immunotherapy, especially immune checkpoint Blockers, the immune system of the body in improving the zone have shown

remarkable success. To recognize and combat cancer cells. Combinatorial approaches, integrating immunotherapy with traditional treatments, are under exploration to enhance therapeutic outcomes. The integration of immunotherapy with traditional modalities presents a synergistic approach, enhancing the overall therapeutic effect. Targeted treatments, directed at specific molecular pathways, further exemplify the move towards precision medicine. Advancements in personalized therapies represent a paradigm shift in the field of medicine, tailoring treatment approaches. Precision medicine allows customization of treatments for individual patients by considering their distinct genetic, molecular, and clinical characteristics. more targeted and effective approach to managing various diseases, including cancer. Genomic profiling and molecular diagnostics play pivotal roles in identifying specific genetic alterations or biomarkers associated with a patient's condition. As these advancements progress, ongoing clinical trials play a pivotal role in validating their efficacy, safety, and long-term impact on patient survival and quality of life. Personalized Medicine and Genomic Profiling, Public Health Initiatives and Prevention, Epidemiology and Risk Factors, Clinical Presentation and Diagnosis and Treatment Modalities. the DEMATEL-based ranking of Advancements in Personalized Therapies for Head and Neck Cancer, Personalized Medicine and Genomic Profiling secure the top position, while Clinical Presentation and Diagnosis obtain the lowest rank.

REFERENCES

- [1]. Watson, Geoffrey Alan, Kirsty Taylor, and Lillian L. Siu. "Innovation and advances in precision medicine in head and neck cancer." In *Critical Issues in Head and Neck Oncology: Key Concepts from the Seventh THNO Meeting*, pp. 355-373. Cham: Springer International Publishing, 2021.
- [2]. Solis, Roberto N., Dustin A. Silverman, and Andrew C. Birkeland. "Current trends in precision medicine and next-generation sequencing in head and neck cancer." *Current treatment options in oncology* 23, no. 2 (2022): 254-267.
- [3]. Polverini, P. J., N. J. D'Silva, and Y. L. Lei. "Precision therapy of head and neck squamous cell carcinoma." *Journal of dental research* 97, no. 6 (2018): 614-621.
- [4]. Sabina Ashfaque Shaikh, "Intelligent Tutoring Systems and Personalized Learning: A Thorough Secondary Research Examination." *International Journal of Research & Technology* 13, no. S4 (2025): 533-543.
- [5]. Tirumala Rao Gundala, "Performance Optimization in Large-Scale Database Migration A MultiAlgorithm Assessment", *Journal of Business Intelligence and Data Analytics*, 1(3), 2024, 1-6.
- [6]. Rakesh Mittapally. "Assessing Normality in Healthcare Expenditure Data: A Shapiro-Wilk Test Approach In P"thons." *International Journal of Computer Science and Data Engineering* 2, no. 4 (2025): 1-8.
- [7]. Kemmer, J. D., D. E. Johnson, and J. R. Grandis. "Leveraging genomics for head and neck cancer treatment." *Journal of dental research* 97, no. 6 (2018): 603-613.
- [8]. Parsel, Sean M., Jennifer R. Grandis, and Sufi M. Thomas. "Nucleic acid targeting: towards personalized therapy for head and neck cancer." *Oncogene* 35, no. 25 (2016): 3217-3226.
- [9]. Hoesli, Rebecca C., Megan L. Ludwig, Nicole L. Michmerhuizen, Andrew J. Rosko, Matthew E. Spector, J. Chad Brenner, and Andrew C. Birkeland. "Genomic sequencing and precision medicine in head and neck cancers." *European Journal of Surgical Oncology (EJSO)* 43, no. 5 (2017): 884-892.
- [10]. Divya Soundarapandian, "Machine Learning Algorithms for Optimizing Search Personalization and Site Reliability in E-Commerce Platforms: A Comparative Analysis of Linear Regression, SVR, and AdaBoost", *Journal of Artificial Intelligence and Machine Learning*, 3(4), 2025, 1-7.
- [11]. Tirumala Rao Gundala "Oracle OIPA Cloud Migration Analysis: Machine Learning Models for Predicting Resource Utilization and Success Outcomes." *International Journal of Artificial intelligence and Machine Learning* 2, no. 3 (2024): 1-8.
- [12]. Uchampalli, Dipak, E. Girish Kumar, and S. Vikrant. "Ecosystem services-an overview." *Indian Journal of Economics and Development* 5, no. 7 (2017): 1-5.
- [13]. Rakesh Mittapally, "Data-Driven Prediction of Mechanical Properties in 3D-Printed Composites Using Hybrid Machine Learning Models." *Journal of Data Science and Information Technology* 2, no. 2 (2025): 1-16.
- [14]. Pryor, David I., Benjamin Solomon, and Sandro V. Porceddu. "The emerging era of personalized therapy in squamous cell carcinoma of the head and neck." *Asia-Pacific Journal of Clinical Oncology* 7, no. 3 (2011): 236-251.
- [15]. Kordbacheh, Farzaneh, and Camile S. Farah. "Current and emerging molecular therapies for head and neck squamous cell carcinoma." *Cancers* 13, no. 21 (2021): 5471.
- [16]. van Harten, Anne M., and Ruud H. Brakenhoff. "Targeted treatment of head and neck (pre) cancer: preclinical target identification and development of novel therapeutic applications." *Cancers* 13, no. 11 (2021): 2774.
- [17]. Galmiche, Antoine, Zuzana Saidak, Jebrane Bouaoud, Haitham Mirghani, Cyril Page, Stéphanie Dakpé, and Florian Clatot. "Genomics and precision surgery for head and neck squamous cell carcinoma." *Cancer Letters* 481 (2020): 45-54.

- [18].Miss Shaikh Mantasha Mohammad Zafar, Miss Rehmat Sabir Qureshi, Sabina Ashfaq Shaikh, "Transformative Impact of Artificial Intelligence on Commerce." *International Journal of Research & Technology* 13, no. S4 (2025): 291-298.
- [19].Vimala Saravanan, M. Ramachandran, Arunambigai Rames, Anusuya Mohan, "Electrical Evolution in Modern Aircraft: Advancements and Challenges" *Building Materials and Engineering Structures*, 3(2), June 2025, 15-27.
- [20].Dipak Uchampalli, "Understanding the Impact of Climate Change on Soil Health and Ecosystem Resilience" *trends in finance and economics*, 3(1), 2025, 53-62.
- [21].Nitika, J Kaur, R Khanna, Novel monkey-wrench-shaped microstrip patch sensor for food evaluation and analysis, "International Journal of RF and Microwave Computer-Aided Engineering", 102(4), 2022, 1443-1456.
- [22].Karthik Perikala, "Architecting Retail-Scale Vector Store Systems for Agentic Generative AI", *International Journal of Computer Engineering and Technology (IJCET)*, 17(1), 2026, 1-14. DOI: 10.34218/IJCET_17_01_001
- [23].Ghosh, Soma, Pooja A. Shah, and Faye M. Johnson. "Novel systemic treatment modalities including immunotherapy and molecular targeted therapy for recurrent and metastatic head and neck squamous cell carcinoma." *International journal of molecular sciences* 23, no. 14 (2022): 7889.
- [24].Affolter, Annette, Anne Lammert, Johann Kern, Claudia Scherl, and Nicole Rotter. "Precision medicine gains momentum: Novel 3D models and stem cell-based approaches in head and neck cancer." *Frontiers in Cell and Developmental Biology* 9 (2021): 666515.
- [25].SK Yadav, A Kaur, R Khanna, "An ultra-wideband "OM" shaped DRA with a defected ground structure and dual polarization properties for 4G/5G wireless communications", *International Journal of RF and Microwave Computer-Aided Engineering*, 30(8), 1-18, 2020.
- [26].Karthik Perikala, "A Modular Benchmarking Framework for Evaluating LLM-Based Agent Applications", *International Journal of Research in Computer Applications and Information Technology (IJRCAIT)*, 9(1), 2026, 1-14. DOI: https://doi.org/10.34218/IJRCAIT_09_01_001
- [27].Shibata, Hirofumi, Liye Zhou, Na Xu, Ann Marie Egloff, and Ravindra Uppaluri. "Personalized cancer vaccination in head and neck cancer." *Cancer Science* 112, no. 3 (2021): 978-988.
- [28].Lee, Wen-Shiung, Alex YiHou Huang, Yong-Yang Chang, and Chiao-Ming Cheng. "Analysis of decision-making factors for equity investment by DEMATEL and Analytic Network Process." *Expert Systems with Applications* 38, no. 7 (2011): 8375-8383.
- [29].Kurinjimalar Ramu, M. Ramachandran, and Malarvizhi Mani. "Evaluation of Marine Currents Energy Plant Using DETMAL MCDM Method." (2022).
- [30].Tsai, Wen-Hsien, and Wen-Chin Chou. "Selecting management systems for sustainable development in SMEs: A novel hybrid model based on DEMATEL, ANP, and ZOGP." *Expert systems with applications* 36, no. 2 (2009): 1444-1458.
- [31].Chandrasekar Raja, M. Ramachandran, Anusuya Mohan, Arunambigai Ramesh, "Evaluation of Embedded Intelligent real time systems by using MOORA method" *Data Analytics and Artificial Intelligence*, 5(1), 2025, 126-136
- [32].Sukumaran, C., K. Indhumathi, P. Balamurugan, R. P. Ambilwade, P. Mohana Sunthari, and L. Natrayan. "The role of AI in biochips for early disease detection." In *2023 3rd International Conference on Technological Advancements in Computational Sciences (ICTACS)*, pp. 1323-1328. IEEE, 2023.
- [33].Divya Soundarapandian, "Algorithmic Framework for Retail Media Optimization and Consumer Engagement Enhancement", *Journal of Business Intelligence and Data Analytics*, 1(3), 2024, 1-7.
- [34].Kumar, Ashwani, and Gaurav Dixit. "An analysis of barriers affecting the implementation of e-waste management practices in India: A novel ISM-DEMATEL approach." *Sustainable Production and Consumption* 14 (2018): 36-52.
- [35].Si, Sheng-Li, Xiao-Yue You, Hu-Chen Liu, and Ping Zhang. "DEMATEL technique: A systematic review of the state-of-the-art literature on methodologies and applications." *Mathematical Problems in Engineering* 2018 (2018).
- [36].Yazdi, Mohammad, Faisal Khan, Rouzbeh Abbassi, and Risza Rusli. "Improved DEMATEL methodology for effective safety management decision-making." *Safety science* 127 (2020): 104705.
- [37].Zhang, Weiquan, and Yong Deng. "Combining conflicting evidence using the DEMATEL method." *Soft computing* 23, no. 17 (2019): 8207-8216.
- [38].Sukumaran, C., M. Ramachandran, Chinnasami Sivaji, and Manjula Selvam. "Ranking of Product in E-store using WASPAS method." *REST Journal on Banking, Accounting and Business* 1, no. 1 (2022): 1-9.
- [39].Lee, Hsuan-Shih, Gwo-Hshiung Tzeng, Weichung Yeih, Yu-Jie Wang, and Shing-Chih Yang. "Revised DEMATEL: resolving the infeasibility of DEMATEL." *Applied Mathematical Modelling* 37, no. 10-11 (2013): 6746-6757.